MYO16 and neoplasm: As shown in Fig. 1C, MYO16-AS1 expression was significantly downregulated in cancer tissue compared with normal tissue, consistent with the results of noncoding RNA sequencing (Fig. 1B), TCGA database analysis (Fig. 1D) and analysis of the GSE168466 dataset (Figure S1B); furthermore, MYO16-AS1 expression was downregulated at both early and late tumor stages relative to that in normal tissue (Figure S1C).